Probing the weak mixing angle at high energy

The weak mixing angle is a probe of the vector-axial coupling structure of electroweak interactions. It has been measured precisely at the $Z$-pole by experiments at the LEP and SLD colliders, but its energy dependence above $M_Z$ remains unconstrained. In this contribution we propose to exploit measurements of Neutral-Current Drell Yan at large invariant dilepton masses at the Large Hadron Collider, to determine the scale dependence of the weak mixing angle in the $\overline{MS}$ renormalisation scheme, $\sin^2 \theta_w^{\overline{MS}}(\mu)$. Such a measurement can be used to test the Standard Model predictions for the $\overline{MS}$ running at TeV scales, and to set model-independent constraints on new states with electroweak quantum numbers. To this end, we present an implementation of $\sin^2 \theta_w^{\overline{MS}}(\mu)$ in the POWHEG-BOX Monte Carlo event generator, which we use to explore the potential of future analyses with the LHC Run~3 and High-Luminosity datasets. In particular, the impact of the higher order corrections and of the uncertainties due to the knowledge of parton distribution functions are studied.Comment: Presented at DIS2023 - XXX International Workshop on Deep-Inelastic Scattering and related subject

On electroweak corrections to neutral current Drell–Yan with the POWHEG BOX

Abstract Motivated by the requirement of a refined and flexible treatment of electroweak corrections to the neutral current Drell–Yan process, we report on recent developments on various input parameter/renormalization schemes for the calculation of fully differential cross sections, including both on-shell and $$\overline{ \mathrm MS}$$ M S ¯ schemes. The latter are particularly interesting for direct determinations of running couplings at the highest LHC energies. The calculations feature next-to-leading order precision with additional higher order contributions from universal corrections such as $$\varDelta \alpha$$ Δ α and $$\varDelta \rho$$ Δ ρ . All the discussed input parameter/renormalization scheme options are implemented in the package of POWHEG-BOX-V2 dedicated to the neutral current Drell–Yan simulation, i.e. Z_ew-BMNNPV, which is used to obtain the presented numerical results. In particular, a comprehensive analysis on physical observables calculated with different input parameter/renormalization    schemes is presented, addressing the Z peak invariant mass region as well as the high energy window. We take the opportunity of reporting also on additional improvements and options introduced in the package Z_ew-BMNNPV after svn revision 3376, such as different options for the treatment of the hadronic contribution to the running of the electromagnetic coupling and for the handling of the unstable Z resonance

Probing the Weak Mixing Angle at high energies at the LHC

The electroweak mixing angle is a fundamental parameter of the theory of electroweak interactions. Its value has been measured precisely at the $\mathrm{Z}$-pole at colliders. In this contribution, we propose to exploit measurements of Neutral-Current Drell-Yan production at the Large Hadron Collider at large invariant dilepton masses to determine the energy scale dependence (running) of the electroweak mixing angle in the $\overline{\text{MS}}$ renormalisation scheme, $\sin^2\theta_{W,\ell}^{\overline{\text{MS}}}(\mu)$. Such a measurement can be used to confirm the Standard Model predictions for the $\overline{\text{MS}}$ running at $\text{TeV}$ scales, and to set model-independent constraints on new states with electroweak quantum numbers. To this end, we make use of a dedicated implementation of $\sin^2\theta_{W,\ell}^{\overline{\text{MS}}}(\mu)$ in the POWHEG-BOX-V2 Monte Carlo event generator, which we use to explore the potential of future analyses using the data of the LHC Run 3 and High-Luminosity

Probing the Weak Mixing Angle at high energies at the LHC

The electroweak mixing angle is a fundamental parameter of the theory of electroweak interactions. Its value has been measured precisely at the $\mathrm{Z}$-pole at colliders. In this contribution, we propose to exploit measurements of Neutral-Current Drell-Yan production at the Large Hadron Collider at large invariant dilepton masses to determine the energy scale dependence (running) of the electroweak mixing angle in the $\overline{\text{MS}}$ renormalisation scheme, $\sin^2\theta_{W,\ell}^{\overline{\text{MS}}}(\mu)$. Such a measurement can be used to confirm the Standard Model predictions for the $\overline{\text{MS}}$ running at $\text{TeV}$ scales, and to set model-independent constraints on new states with electroweak quantum numbers. To this end, we make use of a dedicated implementation of $\sin^2\theta_{W,\ell}^{\overline{\text{MS}}}(\mu)$ in the POWHEG-BOX-V2 Monte Carlo event generator, which we use to explore the potential of future analyses using the data of the LHC Run 3 and High-Luminosity

First investigation of the running of the electroweak mixing angle

The weak mixing angle is a probe of the vector-axial coupling structure of electroweak interactions. It has been measured precisely at the Z-pole by experiments at the LEP and SLD colliders, but its energy dependence above mZ remains unconstrained.In this contribution we propose to exploit measurements of Neutral-Current Drell-Yan production at the Large Hadron Collider at large invariant dilepton masses to determine the scale dependence of the weak mixing angle in the MSbar renormalisation scheme, sin2θW(μ).Such a measurement can be used to confirm the Standard Model predictions for the MSbar running at TeV scales, and to set model-independent constraints on new states with electroweak quantum numbers.To this end, we present an implementation of sin2θW(μ) in a Monte Carlo event generator in Powheg-Box, which we use to explore the potential of future dedicated analyses with the LHC Run3 and High-Luminosity datasets.In particular, we study the impact of higher order electroweak corrections and of uncertainties due the knowledge of parton distribution functions

Probing the weak mixing angle at high energies at the LHC and HL-LHC

Measurements of neutral current Drell-Yan production at large invariant dilepton masses can be used to test the energy scale dependence (running) of the electroweak mixing angle. In this work, we make use of a novel implementation of the full next-to-leading order electroweak radiative corrections to the Drell-Yan process using the $\overline{\mathrm{MS}}$ renormalization scheme for the electroweak mixing angle. The potential of future analyses using proton-proton collisions at $\sqrt{s}=13.6~\mathrm{TeV}$ in the Run 3 and High-Luminosity phases of the LHC is explored. In this way, the Standard Model predictions for the $\overline{\mathrm{MS}}$ running at $\mathrm{TeV}$ scales can be probed

Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study

The aims of this study is to evaluate the association between angiotensin-converting enzyme inhibitor (ACE-I), angiotensin II receptor blocker (ARBs) and/or statin use with the risk of pneumonia, as well as and with in-hospital and short-term outpatient mortality in hospitalized older patients with pneumonia. Patients aged 65 years or older hospitalized in internal medicine and/or geriatric wards throughout Italy and enrolled in the REPOSI (REgistro Politerapuie SIMI-Societa Italiana di Medicina Interna) register from 2010 to 2019 were screened to assess the diagnosis of pneumonia and classified on whether or not they were prescribed with at least one drug among ACE-I, ARBs, and/or statins. Further study outcomes were mortality during hospital stay and at 3 months after hospital discharge. Among 5717 cases included (of whom 18.0% with pneumonia), 2915 (51.0%) were prescribed at least one drug among ACE-I, ARBs, and statins. An inverse association was found between treatment with ACE-I or ARBs and pneumonia (OR = 0.79, 95% CI 0.65-0.95). A higher effect was found among patients treated with ACE-I or ARBs in combination with statins (OR = 0.67, 95% CI 0.52-0.85). This study confirmed in the real-world setting that these largely used medications may reduce the risk of pneumonia in older people, who chronically take them for cardiovascular conditions

Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study

: The aims of this study is to evaluate the association between angiotensin-converting enzyme inhibitor (ACE-I), angiotensin II receptor blocker (ARBs) and/or statin use with the risk of pneumonia, as well as and with in-hospital and short-term outpatient mortality in hospitalized older patients with pneumonia. Patients aged 65 years or older hospitalized in internal medicine and/or geriatric wards throughout Italy and enrolled in the REPOSI (REgistro Politerapuie SIMI-Società Italiana di Medicina Interna) register from 2010 to 2019 were screened to assess the diagnosis of pneumonia and classified on whether or not they were prescribed with at least one drug among ACE-I, ARBs, and/or statins. Further study outcomes were mortality during hospital stay and at 3 months after hospital discharge. Among 5717 cases included (of whom 18.0% with pneumonia), 2915 (51.0%) were prescribed at least one drug among ACE-I, ARBs, and statins. An inverse association was found between treatment with ACE-I or ARBs and pneumonia (OR = 0.79, 95% CI 0.65-0.95). A higher effect was found among patients treated with ACE-I or ARBs in combination with statins (OR = 0.67, 95% CI 0.52-0.85). This study confirmed in the real-world setting that these largely used medications may reduce the risk of pneumonia in older people, who chronically take them for cardiovascular conditions

Drug prescription appropriateness in hospitalized older patients: 15-year results and lessons from a countrywide register.

The global increase of aging with the related increase of multiple noncommunicable diseases is inevitably accompanied by the associated issue of multimorbidity and polypharmacy. The latter is not without peculiar consequences on health, because it has been shown to be associated with drug-related adverse events, mainly due to poor prescription appropriateness and drug-drug interactions. To contribute to tackle this gigantic problem, a registry of drug dispensation in hospitalized older patient has been initiated in Italy in 2008. Through the last 15 years, data on nearly 11,000 older people have been accrued during their hospital stay in internal medicine and geriatric wards. This review article summarizes the main findings obtained, and how these data contribute to tackle the issue of appropriateness of drug prescription and the need of deprescribing in hospitalized older people affected by the most common noncommunicable diseases